PELP-1 promotes adverse endocrine therapy response in ER plus breast cancer

被引：0
|
作者：
Rees, Michael [1 ]
Smith, Chris [2 ]
Barrett-Lee, Peter [1 ]
Hiscox, Stephen [2 ]
机构：
[1] Velindre Canc Ctr, Cardiff, S Glam, Wales
[2] Cardiff Univ, Cardiff, S Glam, Wales
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2884
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2884
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Mutation signature of patients with ER plus metastatic breast cancer who received endocrine therapy.
    Ma, Fei
    Zhang, Yan
    Ouyang, Quchang
    Dai, Pingping
    Yi, Zongbi
    Cao, Weiguo
    Zhou, Yidong
    Zhu, Chenchen
    Guan, Yan-Fang
    Yang, Ling
    Yi, Xin
    Xia, Xuefeng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER plus Breast Cancer Cells
    Castellaro, Andres M.
    Rodriguez-Baili, Maria C.
    Di Tada, Cecilia E.
    Gil, German A.
    CANCERS, 2019, 11 (02)
  • [33] Adenylosuccinate lyase enzyme is essential for growth of endocrine therapy resistant ER plus breast cancer cells
    Yadav, Anil K.
    Clarke, Robert
    Sengupta, Surojeet
    CANCER RESEARCH, 2023, 83 (07)
  • [34] EVIDENCE FOR A CENTRAL ROLE FOR PELP-1 IN ANDROGEN RECEPTOR MEDIATED GENOMIC SIGNALING IN PROSTATE CANCER
    Yang, Lin
    Ravindranathan, Preethi
    Hsieh, J. T.
    Raj, Ganesh
    JOURNAL OF UROLOGY, 2010, 183 (04): : E498 - E499
  • [35] The expression of ERβcx in human breast cancer and the relationship to response to endocrine therapy and survival.
    Palmieri, C
    Lam, E
    Mansi, J
    Madden, P
    Warner, M
    Gustafsson, JA
    Coombes, RC
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S62 - S62
  • [36] Targeting estrogen-regulated system xc- promotes ferroptosis and endocrine sensitivity of ER plus breast cancer
    Cao, Jiawei
    Zhou, Tong
    Wu, Tao
    Lin, Rixu
    Huang, Ju
    Shi, Dejin
    Yu, Jiawei
    Ren, Yinrui
    Qian, Changrui
    He, Licai
    Wu, Guang
    Dong, Zhixiong
    Yuan, Shaofei
    Gu, Haihua
    CELL DEATH & DISEASE, 2025, 16 (01):
  • [37] Comparison of the sensitivity to endocrine therapy of PR plus /ER- patients and ER plus /PR- patients with HER2+breast cancer
    Hao, X.
    Liu, Y.
    Hui, R.
    Zhang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer
    Ahn, Songyeon
    Park, Jun Hyoung
    Grimm, Sandra L.
    Piyarathna, Danthasinghe Waduge Badrajee
    Samanta, Tagari
    Putluri, Vasanta
    Mezquita, Dereck
    Fuqua, Suzanne A. W.
    Putluri, Nagireddy
    Coarfa, Cristian
    Kaipparettu, Benny Abraham
    CANCER RESEARCH, 2024, 84 (02) : 291 - 304
  • [39] PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER plus ) breast cancer models
    Nardone, Agostina
    Goldstein, Amit
    Shea, Martin J.
    Mithchell, Tamika
    Fu, Xiaoyong
    De Angelis, Carmine
    Hu, Huizhong
    Xu, Xiaowei
    Rajendran, Mahitha
    O'Connor, Mark
    Locker, Gershon
    Hilsenbeck, Susan
    Osborne, Kent
    Schiff, Rachel
    CANCER RESEARCH, 2015, 75
  • [40] Benzothiophene SERMs, SERDs, MERDs, SEMs, and ShERPAs in endocrine-independent ER plus breast cancer therapy
    Thatcher, Gregory
    Tonetti, Debra
    Xiong, Rui
    Patel, Hitisha
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
12345